Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Curaleaf Holdings and Green Thumb Industries are two cannabis stocks aggressive investors can investigate this October, but the available operating results do not establish that either is a buy at its current share price. Curaleaf posted faster Q2 2026 revenue growth and a higher gross margin; Green Thumb reported a larger cash balance and positive operating cash flow. Before investing, compare those business results with each stock’s current valuation, debt and share count.
What the latest quarter says about each stock
The figures below come from Curaleaf Holdings, Inc.’s and Green Thumb Industries Inc.’s Q2 2026 releases. Both reported positive GAAP net income for the quarter. Their adjusted profitability figures are company-defined non-GAAP measures, so they should not be treated as equivalent or as a substitute for operating cash flow.
| Q2 2026 measure | Curaleaf Holdings | Green Thumb Industries |
|---|---|---|
| Listings relevant to U.S. investors | TSX: CURA; OTCQX: CURLF | CSE: GTII; OTCQX: GTBIF |
| Revenue and year-over-year growth | $340.1 million; up 10% | $306.7 million; up 4.6% |
| GAAP net income | $12.5 million from continuing operations | $4.9 million |
| Gross margin | 50% | 45.0%, down from 49.9% a year earlier |
| Cash at quarter end | $107.0 million | $283.6 million |
| Company-reported adjusted profitability | Adjusted EBITDA: $70.1 million | Normalized EBITDA: $84.3 million |
| Operating cash flow | Not stated in the cited Q2 release | $29.0 million |
All dollar figures are U.S. dollars. The quarter-end cash figures are balances at a point in time, while operating cash flow is a measure of cash generated over a period; they answer different questions. Curaleaf says its adjusted EBITDA and related ratios are non-GAAP and not standardized under U.S. GAAP. Green Thumb’s normalized EBITDA is also a company-defined non-GAAP measure. Review each company’s reconciliation and adjustments rather than using the two figures as a direct ranking.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Why Curaleaf may appeal to growth-focused investors
Curaleaf’s 10% year-over-year Q2 revenue increase was the faster of the two companies’ reported growth rates, and its 50% gross margin was higher than Green Thumb’s reported 45.0%. Those results make Curaleaf a candidate for investors looking for recent sales momentum, but a single quarter does not show whether that pace or margin can be sustained.
#1 Best Overall
Management described its “Built for Growth” approach as focused on customer centricity, brand building and operational excellence, and said the strategy was gaining traction. That is Curaleaf CEO Boris Jordan’s interpretation of the results, not independent confirmation that the strategy will deliver future returns.
Risks to weigh
Curaleaf’s Q2 2026 filing identifies risks that include regulatory oversight and changes to cannabis or hemp laws, share-price volatility, limited liquidity for U.S. investors, leverage and debt management, competition, agricultural operations, and uncertainty in forecasting. The filing’s list is not a guarantee that every risk will materialize, nor is it exhaustive. Investors should assess the company’s debt and potential dilution alongside its operating growth.
Rank #2
- Comes with secure packaging
- Easy to read text
- It can be a gift option
Why Green Thumb may appeal to cash-conscious investors
Green Thumb reported $283.6 million in quarter-end cash, compared with Curaleaf’s $107.0 million, and $29.0 million of operating cash flow for Q2 2026. Its $4.9 million of GAAP net income was positive, although below Curaleaf’s reported $12.5 million from continuing operations. A larger cash balance can offer more financial flexibility, but it does not by itself establish the company’s overall financial strength; debt, obligations and future cash needs also matter.
Free tools Windows power users keep installed
One-click scans. No signup required.
Margin pressure and market reach
Green Thumb said its gross margin fell to 45.0% from 49.9% a year earlier, attributing the decline principally to licensing fees and price compression. The company also cited increased competition. Its Q2 filing described operations in 14 U.S. markets as of June 30, 2026. That footprint indicates geographic presence, not unrestricted cannabis commerce across the country; legal and market conditions differ by jurisdiction.
Green Thumb CEO Ben Kovler said the team continued to drive top-line growth despite pricing pressure in key markets. This is management commentary; the reported margin decline is a concrete reason for investors to examine whether revenue growth is translating into durable profitability.
What “buy in October” requires beyond earnings
Growth and positive net income describe recent operating performance. They do not show whether a stock is attractively priced. The Q2 releases do not establish what an investor would pay for either company on October 3, 2026, or whether that price reflects expectations for future growth.
Before making a purchase decision, check current market data and filings for:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- Share price and valuation: Compare market capitalization and enterprise value with revenue, earnings and cash flow, using consistent measures and dates. Do not infer that faster growth makes a stock cheap.
- Debt and capital structure: Review borrowings, repayment terms, interest costs and other obligations. Consider whether the company may need to issue shares, which could dilute existing shareholders.
- Cash generation: Look at operating cash flow over more than one quarter and compare it with spending needs and debt service. Do not substitute EBITDA for cash flow.
- Operating durability: Test whether sales growth can persist if competition and price compression continue, and whether gross margins hold up.
- Trading and legal exposure: Confirm the listing and trading liquidity available through your broker, and consider the regulatory uncertainty across the jurisdictions where each company operates.
These checks are particularly important for aggressive investors: the potential for substantial gains comes with exposure to volatility, regulation, competition and company-specific execution. The operating metrics above can help identify questions to investigate; they cannot replace a valuation analysis or determine which stock offers better future returns.
Best Value
October results that could change the comparison
Tilray had a Q1 FY2027 results event scheduled for October 8, 2026, five days after the October 3, 2026 research date for this comparison. Tilray is not one of the two candidates analyzed here, but its results could update the broader set of publicly traded cannabis companies an investor considers. Anyone reading this after October 8 should check whether the event occurred and review Tilray’s published results before relying on an October comparison.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
